1834 Investment Advisors Co. increased its stake in CVS Health Corporation by 4.7%, now holding 121,439 shares valued at approximately $8.2 million. CVS Health reported earnings of $1.81 per share for the last quarter, surpassing analysts' estimates of $1.46, with a revenue of $98.92 billion. The company declared a quarterly dividend of $0.665 per share, reflecting an annualized dividend yield of 4.2%. CVS Health makes up 1.1% of 1834 Investment Advisors Co.'s portfolio, making the stock its 26th biggest position. A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of CVS Health by 0.8% in the first quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator's stock valued at $8,017,223,000 after buying an additional 969,027 shares during the period. Dodge & Cox lifted its stake in shares of CVS Health by 11.2% in the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after buying an additional 7,075,209 shares during the period. Capital World Investors lifted its stake in shares of CVS Health by 26.6% in the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after buying an additional 12,819,148 shares during the period. Capital International Investors lifted its stake in shares of CVS Health by 4.8% in the fourth quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock valued at $1,196,989,000 after buying an additional 1,212,126 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of CVS Health by 5.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator's stock valued at $924,643,000 after buying an additional 728,924 shares during the period. Hedge funds and other institutional investors own 80.66% of the company's stock. Shares of CVS Health traded up $1.91 on Friday, reaching $65.49. 6,458,438 shares of the company's stock were exchanged, compared to its average volume of 9,248,730. The company has a fifty day moving average of $64.68 and a 200-day moving average of $64.31. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $72.51. The company has a market capitalization of $83.06 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 0.72 and a beta of 0.58. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. CVS Health ( - ) last announced its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The firm had revenue of $98.92 billion for the quarter, compared to analyst estimates of $94.87 billion. During the same quarter in the prior year, the business posted $1.83 EPS. The business's revenue was up 8.4% compared to the same quarter last year. On average, research analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year. The company also recently declared a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Tuesday, July 22nd were given a dividend of $0.665 per share. The ex-dividend date was Tuesday, July 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.1%. CVS Health's dividend payout ratio (DPR) is currently 74.30%. Analysts Set New Price Targets CVS has been the subject of a number of research analyst reports. UBS Group dropped their target price on shares of CVS Health from $71.00 to $67.00 and set a 'neutral' rating for the company in a research note on Tuesday, July 22nd. Jefferies Financial Group boosted their price objective on shares of CVS Health from $74.00 to $80.00 and gave the stock a 'buy' rating in a research report on Monday, June 30th. Royal Bank Of Canada boosted their price objective on shares of CVS Health from $74.00 to $81.00 and gave the stock an 'outperform' rating in a research report on Monday, May 5th. Truist Financial boosted their price objective on shares of CVS Health from $82.00 to $84.00 and gave the stock a 'buy' rating in a research report on Monday, May 12th. Finally, upgraded shares of CVS Health from a 'hold' rating to a 'buy' rating in a research report on Friday, May 9th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of 'Moderate Buy' and an average price target of $75.11. Insider Activity In other news, Director purchased 1,570 shares of CVS Health stock in a transaction that occurred on Thursday, June 5th. The shares were acquired at an average price of $63.70 per share, for a total transaction of $100,009.00. Following the transaction, the director owned 12,007 shares of the company's stock, valued at approximately $764,845.90. The trade was a 15.04% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through. Corporate insiders own 1.22% of the company's stock.

1834 Investment Advisors Co. Boosts Stake in CVS Health Corporation (NYSE:CVS)

1834 Investment Advisors Co. increased its stake in CVS Health Corporation by 4.7%, now holding 121,439 shares valued at $8.2 million. CVS Health reported quarterly earnings of $1.81 per share, exceeding analyst estimates of $1.46, with revenue of $98.92 billion and a net margin of 1.17%. The company declared a quarterly dividend of $0.665 per share, resulting in an annualized dividend yield of 4.2%. Multiple hedge funds, including Vanguard Group, Dodge & Cox, Capital World Investors, Capital International Investors, and Charles Schwab, also increased their holdings in CVS Health during the first and fourth quarters. The company has a market capitalization of $83.06 billion, a price-to-earnings ratio of 18.29, and a debt-to-equity ratio of 0.74. Analysts have adjusted price targets, with UBS lowering its target to $67.00 and Jefferies, Royal Bank of Canada, and Truist raising theirs to $80.00, $81.00, and $84.00 respectively, with most assigning a 'buy' rating. A director purchased 1,570 shares at $63.70 per share, increasing their position by 15.04%.